Harry Fisch
Net Worth

Last updated:

What is Harry Fisch net worth?

The estimated net worth of Dr. Harry Fisch is at least $7,137,426 as of 15 May 2024. He owns shares worth $2,581,966 as insider, has earned $835,300 from insider trading and has received compensation worth at least $3,720,160 in Veru Inc..

What is the salary of Harry Fisch?

Dr. Harry Fisch salary is $465,020 per year as Vice Chairman & Chief Corporation Officer in Veru Inc..

How old is Harry Fisch?

Dr. Harry Fisch is 66 years old, born in 1959.

What stocks does Harry Fisch currently own?

As insider, Dr. Harry Fisch owns shares in one company:

Company Title Shares Price per share Total value
Veru Inc. (VERU) Vice Chairman & Chief Corporation Officer 770,736 $3.35 $2,581,966

What does Veru Inc. do?

Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

VERU logo
VERU
Veru Inc.
$3.35

Harry Fisch insider trading

Veru Inc.

Dr. Harry Fisch has made only one insider trade between 2017-2024, according to the Form 4 filled with the SEC. He purchased 6,711 units of VERU stock worth $9,999 on 15 May 2024.

As of 15 May 2024 he still owns at least 770,736 units of VERU stock.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 6,711 $1.49 $9,999
Sale
Common Stock 100,000 $8.35 $835,300
Purchase
Common Stock 5,000 $2.76 $13,800
Purchase
Common Stock 1,000 $4.47 $4,470
Purchase
Common Stock 1,000 $4.51 $4,510
Purchase
Common Stock 10,000 $1.93 $19,250
Purchase
Common Stock 4,000 $1.97 $7,880
Purchase
Common Stock 7,000 $1.92 $13,440
Purchase
Common Stock 3,000 $1.47 $4,410
Purchase
Common Stock 3,500 $1.47 $5,145
Purchase
Common Stock 3,000 $1.43 $4,290
Purchase
Common Stock 3,500 $1.47 $5,145
Purchase
Common Stock 3,400 $1.39 $4,726
Purchase
Common Stock 5,000 $1.27 $6,350
Purchase
Common Stock 3,000 $1.32 $3,960
Purchase
Common Stock 6,000 $1.3 $7,800
Purchase
Common Stock 5,000 $1.35 $6,750
Purchase
Common Stock 5,000 $1.36 $6,795
Purchase
Common Stock 13,681 $1.36 $18,661
Purchase
Common Stock 30,000 N/A N/A
Purchase
Common Stock 8,000 N/A N/A
Purchase
Common Stock 7,800 N/A N/A
Purchase
Common Stock 5,000 N/A N/A
Purchase
Common Stock 10,000 N/A N/A
Purchase
Common Stock 10,000 N/A N/A
Purchase
Common Stock 10,000 N/A N/A
Purchase
Common Stock 10,000 N/A N/A
Purchase
Common Stock 25,000 N/A N/A
Purchase
Common Stock 24,000 N/A N/A
Purchase
Common Stock 20,000 N/A N/A
Purchase
Common Stock 34,250 N/A N/A
Purchase
Common Stock, par value $.01 per share 12,000 N/A N/A
Purchase
Common Stock, par value $.01 per share 10,000 N/A N/A
Purchase
Common Stock, par value $.01 per share 19,750 N/A N/A
Purchase
Common Stock, par value $.01 per share 5,000 N/A N/A

Veru key executives

Veru Inc. executives and other stock owners filed with the SEC: